Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-10-08
1999-12-07
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 23, 514 54, 514 60, 514549, 514552, 514558, 514560, A61K 3800, A61K 3170, A61K 31715, A61K 3122
Patent
active
059983639
ABSTRACT:
An improved enteral formulation that is low in fat and contains protein hydrolysates has been developed. The osmolality of the formulation is controlled to be below 500 mOs/kg H.sub.2 O, preferably about 300 mOs/kg H.sub.2 O. In a preferred embodiment, the formulation contains corn starch to control blood glucose levels. This formulation is particularly useful for treatment of critically ill patients and in minimizing a risk of pulmonary aspiration and/or gastrointestinal dysfunction in such patients.
REFERENCES:
patent: 3698912 (1972-10-01), Winitz
patent: 4438144 (1984-03-01), Blackburn
patent: 4528197 (1985-07-01), Blackburn
patent: 4959350 (1990-09-01), Frokjaer et al.
patent: 5106836 (1992-04-01), Clemens et al.
patent: 5189016 (1993-02-01), Madsen et al.
patent: 5229136 (1993-07-01), Mark et al.
patent: 5298493 (1994-03-01), Mendy
patent: 5403972 (1995-04-01), Valentine
patent: 5405835 (1995-04-01), Mendy
patent: 5438042 (1995-08-01), Schmidl et al.
patent: 5454411 (1995-10-01), Chancellor
Donald, P., et al., "Repletion of Nutritional Parameters in Surgical Patients Receiving Peptide Versus Amino Acid Elemental Feedings", Nutrition Research, vol. 14, 3-12, 1994.
Dutton, E., et al., "Medium-Chain Triglycerides in Neonatal Nutrition" American Journal of Perinatology, vol. 4, No. 1, 5-7, 1987.
Hamilton, C., et al. 17th Clinical Congress Abstracts, vol. 17, No. 1, supplement 31S, 1993.
Heimburger, D.C., et al. 18th Clinical Congress Abstracts, vol. 18, No. 1, supplement 21S, 1994.
McBurney, M.I., et al., 16th Clinical Congress Abstracts, vol. 16, No. 1, supplement 18S, 1992.
Mowatt-Larssen, C.A., 15th Clinical Congress Abstracts, vol. 15, No. 1, supplement 32S, 1991.
Simko, V., et al. Digestive Diseases, vol. 21, No. 5, 419-425, 1976.
Bell Stacey J.
Burke Peter
Forse R. Armour
Beth Israel Deaconess Medical Center Inc.
Henley III Raymond
LandOfFree
Enteral formulation: low in fat and containing protein hydrolysa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enteral formulation: low in fat and containing protein hydrolysa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enteral formulation: low in fat and containing protein hydrolysa will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-823747